HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaque
¥9900 | |
Z06679-100 | |
|
|
|
|
|
¥9900 | |
Z06679-100 | |
|
|
|
|
|
Species | Rhesus macaque | ||||||
Protein Construction |
|
||||||
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaque at 5μg/ml (100μl/well) on the plate can bind Rhesus macaque LILRB1, hFc Tag. Test result was comparable to standard batch. | ||||||
Expression System | HEK293 | ||||||
Theoretical Molecular Weight | 258 kDa | ||||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaque, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Rhesus macaque LILRB1, hFc Tag with the EC50 of 102 ng/ml determined by ELISA. »
The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaquer is greater than 95% as determined by SEC-HPLC. »
HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaque on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%. »
Rhesus macaque LILRB1, hFc Tag captured on CM5 Chip via Protein A can bind HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Rhesus macaque, His Tag with an affinity constant of 1.74 nM as determined in SPR assay (Biacore T200). »
Target Background | HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition. |
Synonyms | HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.